BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ablynx And Domantis Limited Settle Their Dispute And Stop The Arbitration Process


10/12/2009 10:25:42 AM

GHENT, BELGIUM--(Marketwire - October 12, 2009) -


GHENT, Belgium, 12 October, 2009 - Ablynx [Euronext Brussels: ABLX], today announced that it has reached a settlement with Domantis (part of the GlaxoSmithKline group of companies) concerning an alleged dispute relating to a settlement agreement which Ablynx and Domantis entered into in 2005.

Under the new agreement Ablynx has received a license to the European Winter II patent which lay at the heart of the dispute and in return will pay Domantis low single-digit royalties on the first five Nanobody® products which are commercialised.

Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are very pleased to have settled with Domantis so that we can focus on our key goal of developing Nanobody® products and driving them through the clinic. We believe our investors want us, where possible, to put our resources into R&D productivity rather than litigation. The fact that there are two Nanobodies® in Phase II trials, and by the end of 2009 there will be a total of four in the clinic, is a testimony to the power and promise of our technology."

Attachments: Complete version of the press release in English: http://hugin.info/137912/R/1347031/323743.pdf

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.


For more information, please contact:

For international media enquiries:
College Hill Life Sciences
Sue Charles
Justine Lamond
Dr John McIntyre
t: +44 (0)20 7866 7857
e: Email Contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
+44 (0)7990 570 900
e: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES